Videos

Unmet Needs and the Future of Treatment for AD

The neurocritical care fellow at Massachusetts General Hospital and Brigham and Women’s Hospital discussed findings from a recent study that evaluated patients with COVID-19 and disorders of consciousness. [WATCH TIME: 3 minutes]

Jeffrey L. Cummings, MD, ScD, comments on the unmet needs and future outlook for the Alzheimer’s treatment landscape.

Testing Methods for AD

Using Radiomics-Based MR Fingerprinting to Detect Focal Cortical Dysplasia: Irene Wang, PhD

Dr Cummings relays how testing methods influence the treatment course for Alzheimer’s disease.

Irene Wang, PhD

Using SAGE to Detect Mild Cognitive Impairment Earlier: Douglas Scharre, MD

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided insight on her study presented at AES 2021, which showed that MR fingerprinting can differentiate focal cortical dysplasia from healthy tissue. [WATCH TIME: 4 minutes]

Douglas Scharre, MD

SAGE and BrainTest for Cognitive Assessment and Clinical Trial Enrollment: Douglas Scharre, MD

Outlining the findings from a recent study comparing SAGE to the Mini-Mental State Examination, the director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center stressed the importance of identifying patients at-risk for dementia early on. [WATCH TIME: 6 minutes]

Douglas Scharre, MD

January 12th 2022

Clinical Experience as a Factor in the Inconsistencies of Migraine Care: Anne-Maree Kelly, MD

The director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center discussed benefits of both the pen-and-paper and digital assessments. [WATCH TIME: 7 minutes]

Anne-Maree Kelly, MD

January 12th 2022

Development of SAGE for Early Dementia Detection: Douglas Scharre, MD

The director of the Joseph Epstein Center for Emergency Medicine Research discussed whether years of experience causes variation in the way migraine is diagnosed and treated in an emergency department setting. [WATCH TIME: 2 minutes]

Douglas Scharre, MD

January 11th 2022

AUPN Leadership Minute Episode 17: Getting Along With Neurosurgery

The director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center discussed motivations behind creating the pen-and-paper test, as well as its digital companion. [WATCH TIME: 2 minutes]

Clifton L. Gooch, MD;Rohit Das, MD

January 11th 2022

Next Steps in Understanding Cognitive Decline in Aging MS: Dejan Jakimovski, MD, PhD

Episode 17 of the AUPN Leadership Minute features Rohit Das, MD, of UT Southwestern Medical Center; and Clifton L. Gooch, MD, of the University of South Florida. [WATCH TIME: 7 minutes]

Dejan Jakimovski, MD, PhD

January 11th 2022

Utilizing MR Fingerprinting to Benefit Epilepsy Care: Irene Wang, PhD

The research assistant professor at the Buffalo Neuroimaging Analysis Center provided context on how different forms of multiple sclerosis impact cognitive decline in patients. [WATCH TIME: 4 minutes]

Irene Wang, PhD

The Many Consequences of Insomnia

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided background on the momentum behind MR fingerprinting and its potential in epilepsy care. [WATCH TIME: 3 minutes]

Michael J. Thorpy, MD;Karl Doghramji, MD;Erinn E. Beagin, MD;Nathaniel Fletcher Watson, MD;Vikas Jain, MD, FAASM, FAAFP, CCSH, CPE

Considering Sleep Studies for Insomnia

Panelists discuss the broad range of impact insomnia has on a patient’s health and quality of life.

Michael J. Thorpy, MD;Karl Doghramji, MD;Erinn E. Beagin, MD;Nathaniel Fletcher Watson, MD;Vikas Jain, MD, FAASM, FAAFP, CCSH, CPE

Pros and Cons of Telemedicine for Multiple Sclerosis: Mitzi Joi Williams, MD

A brief review of the value of polysomnography, or sleep studies, in diagnosing patients with insomnia.

Mitzi Joi Williams, MD

Information Sharing, Collaboration in MS Care Amidst the COVID-19 Pandemic: Mitzi Joi Williams, MD

The founder and CEO of Joi Wellness Group Multiple Sclerosis Center explained her reasoning as to why she hopes telemedicine is here to stay. [WATCH TIME: 4 minutes]

Mitzi Joi Williams, MD

January 9th 2022

Awake vs Asleep DBS Impact, Worsened MS Following DMT Discontinuation, Anticoagulation Noninferior to Avoiding it

Discussing the willingness to share data during the pandemic, the founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center spoke to the positive effect of collaboration in the MS field. [WATCH TIME: 2 minutes]

NeurologyLive® Staff

January 8th 2022

Addressing Health Disparities in the US Following COVID-19: Mitzi Joi Williams, MD

Neurology News Network for the week ending January 8, 2022. [WATCH TIME: 3 minutes]

Mitzi Joi Williams, MD

Headache Specialists for Preventative Migraine Treatments

The founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center commented on the effect of the pandemic on needs for underrepresented populations in the multiple sclerosis space, as well as the pros and cons of telehealth. [WATCH TIME: 3 minutes]

Jessica Ailani, MD;Stephanie J. Nahas, MD, MSEd;Rebecca Erwin Wells, MD, MPH;Christopher Gottschalk, MD;Andrew C. Charles, MD

Preventative Migraine Therapies: The ADVANCE Trial and the Future

A discussion on when a patient should be referred to a headache specialist for preventive migraine treatment.

Jessica Ailani, MD;Rebecca Erwin Wells, MD, MPH;Christopher Gottschalk, MD;Stephanie J. Nahas, MD, MSEd;Andrew C. Charles, MD

Monoclonal Antibodies in Development for Alzheimer Disease: Anton Porsteinsson, MD

Jessica Ailani, MD, details how the phase 3 ADVANCE trial will shape the research of future agents for preventive migraine treatment.

Anton P. Porsteinsson, MD

Enacting Necessary Changes to the MS Care Model: Mona Bostick, RDN, LDN, MSCS

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester offered an extensive overview of 3 monoclonal antibodies in development for Alzheimer disease. [WATCH TIME: 9 minutes]

Mona Bostick, RDN, LDN, MSCS

Aducanumab’s Approval for the Treatment of AD

Discussing adaptations to the comprehensive care model in multiple sclerosis, the founder of MS Bites commented on the need to consistently incorporate dietitians. [WATCH TIME: 6 minutes]

Biomarker Assessments and Diagnosing AD

Jeffrey L. Cummings, MD, ScD, discusses the importance of aducanumab, a recently approved treatment for Alzheimer’s disease.

Tailoring Cognitive Behavioral Therapy to PNES, Seizure-Related Disorders, Becky Tilahun, PhD

Jeffrey L. Cummings, MD, ScD, delves into the biomarker assessments that establish a diagnosis of Alzheimer’s disease and their use in clinical practice.

Becky Tilahun, PhD

Dispelling Myths About Dietitians in Multiple Sclerosis Care: Mona Bostick, RDN, LDN, MSCS

The clinical psychologist at Cleveland Clinic discussed the process for successfully changing and tailoring different cognitive behavioral therapy approaches to treat various forms of seizures. [WATCH TIME: 3 minutes]

Mona Bostick, RDN, LDN, MSCS

January 5th 2022

Eliminating Wasteful Costs in Alzheimer Drug Development: Jeffrey Cummings, MD, ScD

The founder of MS Bites discussed the role of referrals both to and from dietitians, as well as the common misconception that their services are not covered by insurance. [WATCH TIME: 2 minutes]

Jeffrey Cummings, MD, ScD

January 5th 2022

Managing Patients With RRMS on Novel Oral Therapy

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success. [WATCH TIME: 4 minutes]

NeurologyLive® Staff

January 5th 2022